– Recognized for Services to Medical Research –
Company Website:
http://www.gilead.com
FOSTER CITY, Calif. -- (Business Wire)
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John
McHutchison, MD, Chief Scientific Officer and Head of Research and
Development, has been appointed an Officer of the Order of Australia in
recognition of his “distinguished service to medical research in
gastroenterology and hepatology, particularly through the development of
treatments for viral infections, and to the biopharmaceutical industry.”
Dr. McHutchison is an internationally recognized leader in
gastroenterology and hepatology, with extensive expertise in clinical
and translational research in liver diseases. He joined Gilead in 2010,
and was appointed Chief Scientific Officer in March 2018. Under his
leadership, Gilead has developed five medicines for the treatment of
chronic hepatitis B and hepatitis C that have been used by nearly 2
million people around the world.
“I am deeply honored to receive this appointment,” said Dr. McHutchison.
“I have been fortunate to work with many gifted and inspiring leaders in
the liver disease field, and I am grateful to them for many years of
collaboration, support and friendship.”
The Order of Australia is awarded to Australian citizens and other
persons for achievement or meritorious service. An individual who is
appointed Officer is recognized for “distinguished service of a high
degree to Australia or to humanity at large.”
“John is an inquisitive and insightful scientist who has helped to
transform the outlook for millions of people with liver disease around
the world,” said John Milligan, PhD, Gilead’s President and CEO. “We
congratulate him on this prestigious recognition and look forward to his
continued leadership of our R&D programs.”
Dr. McHutchison has undergraduate degrees in medicine and surgery from
the University of Melbourne in Australia and completed his residency in
internal medicine and fellowship in gastroenterology at the Royal
Melbourne Hospital. He is a member of the Royal Australasian College of
Physicians.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters in
Foster City, California.
Forward-Looking Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties, and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018, as filed with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
statements.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180611005197/en/
Contacts:
Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Amy
Flood, 650-522-5643
Source: Gilead Sciences, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.